Alzheimer's Disease

A prospective, randomized, double blind, placebo-controlled, phase 2 efficacy and safety study of oral ELND005 for treatment of agitation and aggression in patients with moderate to severe Alzheimer's disease.

Objective

The purpose of this study is to determine whether ELND005 is effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease. Eligible patients will have a diagnosis of moderate to severe Alzheimer’s disease and have significant agitation and/or aggression which has not responded to other treatments.

ClinicalTrials.Gov Number

NCT01735630

Principal Investigator(s)

Nadeem Mirza, MD

Sponsor(s)

Elan Pharma International Limited

Contact

Gail Massey, RN, BS at 269-341-8774
or masseyg@bronsonhg.com

How to Participate

Subjects will be randomly assigned to either the investigational drug or placebo and will be followed for 12 weeks to evaluate the effectiveness and safety of the new drug. About 400 patients will enroll in the study at multiple sites.

More information can be found here.